Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, Chaudhary A, Fife K, Battiato L, Sweeney C, Jordan C, Burgess M, Slapak CA. Sandler A, et al. Among authors: pouliquen i. Clin Cancer Res. 2004 May 15;10(10):3265-72. doi: 10.1158/1078-0432.CCR-03-0644. Clin Cancer Res. 2004. PMID: 15161679 Clinical Trial.
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
Rubin EH, de Alwis DP, Pouliquen I, Green L, Marder P, Lin Y, Musanti R, Grospe SL, Smith SL, Toppmeyer DL, Much J, Kane M, Chaudhary A, Jordan C, Burgess M, Slapak CA. Rubin EH, et al. Among authors: pouliquen i. Clin Cancer Res. 2002 Dec;8(12):3710-7. Clin Cancer Res. 2002. PMID: 12473580 Clinical Trial.
Quinidine does not affect the renal clearance of moxonidine.
Wise SD, Chan C, Schaefer HG, He MM, Pouliquen IJ, Mitchell MI. Wise SD, et al. Among authors: pouliquen ij. Br J Clin Pharmacol. 2002 Sep;54(3):251-4. doi: 10.1046/j.1365-2125.2002.01647.x. Br J Clin Pharmacol. 2002. PMID: 12236844 Free PMC article. Clinical Trial.
22 results